Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

441
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
441

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

The Protein Phosphatase Inhibitor LB100 Targets the Mesenchymal Lineage of Pancreatic Ductal Adenocarcinoma.

MedComm·2026
Same author

Neutrophil-Driven Trogocytosis in Pancreatic Ductal Adenocarcinoma Liver Metastases Restrains Immunosuppressive Macrophage Polarization and Limits Metastatic Progression.

Gastroenterology·2026
Same author

Pancreatic cancer.

Nature reviews. Disease primers·2026
Same author

B cell Maturation Antigen Targeted Chimeric Antigen Receptor T Cell Therapy for Refractory Systemic Lupus Erythematosus and Systemic Sclerosis.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

Corrigendum to Polybromo 1/vimentin axis dictates tumor grade, epithelial-mesenchymal transition, and metastasis in pancreatic cancer.

The Journal of clinical investigation·2026
Same author

A translational colorectal cancer organoid biobank mirrors patients' tumor histology, molecular profiles, and treatment responses.

Journal of experimental & clinical cancer research : CR·2026

相关实验视频

Updated: May 17, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

393

基酶2工程T细胞显示抗瘤功能的增加.

Raphaëlle Toledano Zur1, Shiran Didi Zurinam1, Maria Radman1

  • 1The Laboratory of Tumor Immunology and Immunotherapy, The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat Gan, Israel.

Frontiers in immunology
|April 4, 2025
PubMed
概括

在T细胞中过度表达Hexokinase 2 (HK2) 通过增强新陈代谢来增强其抗瘤反应. 这种工程T细胞疗法显示出在具有挑战性的瘤微环境中改善癌症治疗的前景.

关键词:
这些T细胞是T细胞.在TCR中,可以使用TCR.细胞免疫疗法细胞免疫疗法六基酶 2 的作用.免疫代谢的免疫代谢.

更多相关视频

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

14.7K
Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment
11:11

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment

Published on: January 24, 2020

10.8K

相关实验视频

Last Updated: May 17, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

393
Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

14.7K
Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment
11:11

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment

Published on: January 24, 2020

10.8K

科学领域:

  • 免疫学 免疫学 免疫学
  • 癌症生物学 癌症生物学
  • 代谢工程是代谢工程.

背景情况:

  • 由于癌细胞的营养竞争,T细胞在瘤微环境 (TME) 中进行代谢斗争.
  • 这种竞争会损害T细胞的抗瘤活性,因为它会降低像糖分解这样的关键代谢功能.
  • 基酶2 (HK2) 对于T细胞糖解和整体功能至关重要.

研究的目的:

  • 通过基因工程T细胞来增强T细胞抗瘤免疫力,使T细胞过度表达2 (HK2) 基因酶.
  • 在体外和体内评估HK2工程T细胞的代谢和治疗疗效.

主要方法:

  • 主要的人类T细胞被基因改造以过度表达HK2和瘤特异性受体.
  • 工程T细胞在体外进行了对代谢功能和激活的测试.
  • 在体内有效性使用人类瘤异种移植模型进行评估.

主要成果:

  • 经HK2工程的T细胞显著增加了糖分分解能力.
  • 增强的代谢活性与改善的细胞因子分泌和激活标志物表达相关.
  • 在体内研究显示,异种移植模型中的瘤生长延迟和生存率改善.

结论:

  • 过度表达HK2可以提高T细胞在TME中的代谢适应性和功能.
  • 这种代谢增强转化为改善抗瘤治疗疗效.
  • HK2工程代表了针对T细胞代谢的下一代免疫疗法的一个有前途的战略.